This is a preview of subscription content, log in via an institution to check access.
Notes
Further Cardiovascular Outcomes Research with PCSK9 [proprotein convertase subtilisin/kexin type 9] Inhibition in Subjects with Elevated Risk
Reference
Hernandez I. Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. JAMA Internal Medicine : 7 Aug 2017. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2017.3143
Rights and permissions
About this article
Cite this article
Outcomes-based pricing: effects on evolocumab. PharmacoEcon Outcomes News 785, 24 (2017). https://doi.org/10.1007/s40274-017-4274-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4274-3